Royalty Pharma plc
RPRX · XNASCIK 1802768fmd_0WBVQ94YS0JNMYNWMSMW94JJAMManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2018 to Sep 30, 2026, 31 periods
Latest annual · FY2025
Millions- Total revenues
- 2,378
- Operating income
- 1,560
- Net income
- 771
Latest quarter · Q3 FY2026
Millions- Total revenues
- 690
- Operating income
- 411
- Net income
- 145
Daily close · RPRXIEX trades only
Nov 13, 2025 to Nov 11, 2026 · 250 sessions69.98 USD
Built from trades executed at IEX only, one exchange with a small share of US volume. This is not the consolidated tape. The close is the last IEX trade of the session, not the official closing price. Earlier sessions are divided by the later split ratios the API confirmed against IEX prices; dividends are not adjusted. Switch to As traded for the prices as they printed. End of day, not real time: a session is published the day after it trades.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2022 to FY2025
- +2.1%
- Revenue, 5 yearsFY2020 to FY2025
- +2.3%
- Net income, 5 yearsFY2020 to FY2025
- -4.6%
Royalty Pharma plc (RPRX) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $2.4 billion | $2.3 billion | +5.1% | 10-K 2026-02-11 · proof |
| Operating income | $1.6 billion | $1.3 billion | +20.7% | 10-K 2026-02-11 · proof |
| Net income | $770.9 million | $859 million | -10.2% | 10-K 2026-02-11 · proof |
| Cash from operating activities | $2.5 billion | $2.8 billion | -10.1% | 10-K 2026-02-11 · proof |
| Total assets | $19.6 billion | $18.2 billion | +7.7% | 10-K 2026-02-11 · proof |
| Total liabilities | $9.9 billion | $7.9 billion | +25.7% | 10-K 2026-02-11 · proof |
| Cash and cash equivalents | $618.7 million | $929 million | -33.4% | 10-K 2026-02-11 · proof |
| Total debt | $9 billion | $7.6 billion | +17.6% | 10-K 2026-02-11 · proof |
- What was Royalty Pharma plc (RPRX)'s revenue in fiscal 2025?
- Royalty Pharma plc (RPRX) reported revenue of $2.4 billion for fiscal 2025 (the year ended Dec 31, 2025), against $2.3 billion the year before (+5.1%). Source: the 10-K filed with the SEC on Feb 11, 2026. SEC
- What was Royalty Pharma plc (RPRX)'s operating income in fiscal 2025?
- Royalty Pharma plc (RPRX) reported operating income of $1.6 billion for fiscal 2025 (the year ended Dec 31, 2025), against $1.3 billion the year before (+20.7%). Source: the 10-K filed with the SEC on Feb 11, 2026. SEC
- What was Royalty Pharma plc (RPRX)'s net income in fiscal 2025?
- Royalty Pharma plc (RPRX) reported net income of $770.9 million for fiscal 2025 (the year ended Dec 31, 2025), against $859 million the year before (-10.2%). Source: the 10-K filed with the SEC on Feb 11, 2026. SEC
- What was Royalty Pharma plc (RPRX)'s cash from operating activities in fiscal 2025?
- Royalty Pharma plc (RPRX) reported cash from operating activities of $2.5 billion for fiscal 2025 (the year ended Dec 31, 2025), against $2.8 billion the year before (-10.1%). Source: the 10-K filed with the SEC on Feb 11, 2026. SEC
- What are Royalty Pharma plc (RPRX)'s total assets?
- As of Dec 31, 2025, Royalty Pharma plc (RPRX) reported total assets of $19.6 billion, against $18.2 billion a year earlier (+7.7%). Source: the 10-K filed with the SEC on Feb 11, 2026. SEC
- What are Royalty Pharma plc (RPRX)'s total liabilities?
- As of Dec 31, 2025, Royalty Pharma plc (RPRX) reported total liabilities of $9.9 billion, against $7.9 billion a year earlier (+25.7%). Source: the 10-K filed with the SEC on Feb 11, 2026. SEC
- What are Royalty Pharma plc (RPRX)'s cash and cash equivalents?
- As of Dec 31, 2025, Royalty Pharma plc (RPRX) reported cash and cash equivalents of $618.7 million, against $929 million a year earlier (-33.4%). Source: the 10-K filed with the SEC on Feb 11, 2026. SEC
- What is Royalty Pharma plc (RPRX)'s total debt?
- As of Dec 31, 2025, Royalty Pharma plc (RPRX) reported total debt of $9 billion, against $7.6 billion a year earlier (+17.6%). Source: the 10-K filed with the SEC on Feb 11, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:RPRX&period_type=annual&limit=5"Information only, not investment advice.